SCHEDULE 13D/A: Walgreens Boots Alliance to be Acquired by Sycamore Affiliate; Key Investor Stefano Pessina Reinvests Significant Stake

Walgreens Boots Alliance, Inc. has entered into a definitive merger agreement to be acquired by an entity affiliated with Sycamore Partners, with a significant reinvestment from existing major shareholder Stefano Pessina and Alliance Sant Participations S.A.

Summary

• Walgreens Boots Alliance, Inc. (the "Company") has agreed to be acquired by Blazing Star Parent, LLC, an affiliate of Sycamore Partners, L.P. ("Sycamore").
• The acquisition consideration is $11.45 per share in cash at closing, plus one non-transferable right (a "DAP Right") to receive up to $3.00 per share from the future monetization of the Company's debt and equity interests in VillageMD.
• Mr. Stefano Pessina ("SP") and Alliance Sant Participations S.A. ("ASP," and together with SP, the "SP Investors") have agreed to reinvest their cash consideration from the merger, plus an additional cash amount of $77,638,645, into newly formed parent entities ("Topcos") that will hold the Company's businesses after a restructuring.
• The SP Investors will acquire equity interests in the Topcos at the same price per unit as the Sponsor Parties (Sycamore affiliates).
• As of January 3, 2025, the SP Investors beneficially own an aggregate of 147,615,089 shares of Common Stock, representing approximately 17.1% of the outstanding shares.
• The transaction involves a restructuring of the Company's businesses into separate Topcos prior to the merger closing.
• The SP Investors have entered into a Voting Agreement, committing to vote their shares in favor of the merger and against competing proposals, and have waived appraisal rights.
• An Interim Investors Agreement governs the relationship between the Sycamore Investors and the SP Investors, outlining responsibilities for regulatory filings, expense allocation, and limited liability for the SP Investors regarding certain termination fees.

Sentiment

Score: 7

Explanation: The document details a definitive merger agreement with a clear path to closing, supported by a significant reinvestment from a key existing shareholder. This commitment from a major investor, coupled with favorable terms for their reinvestment and limited liability, indicates a strong alignment and confidence in the transaction's success, despite inherent risks in any complex acquisition.

Positives

• The definitive merger agreement provides a clear path for the Company's acquisition, offering shareholders a cash component and potential upside from VillageMD monetization.
• The significant reinvestment by Stefano Pessina and Alliance Sant Participations S.A. (totaling the "Aggregate Equity Investment Amount") demonstrates strong commitment from a major existing shareholder.
• SP Investors will acquire equity interests in the new Topcos at the same valuation per Topco Interest as the Sponsor Parties, ensuring equitable terms for their reinvestment.
• The Interim Investors Agreement limits the liability of SP Investors, stating they will not be responsible for any portion of the Parent Termination Fee or Parent Damages if the Merger Agreement is terminated under certain circumstances.
• The Saturn Investors (Sycamore affiliates) are responsible for 100% of all HSR Act and other Antitrust Laws filing fees, reducing a potential burden on the SP Investors.

Negatives

• SP Investors have waived their appraisal rights, limiting their recourse to the agreed-upon merger consideration.
• SP Investors are restricted from transferring their shares of Company Common Stock prior to the merger consummation, with limited exceptions.
• Stefano Pessina's employee stock options (1,994,010 shares) are "out-of-the-money," with exercise prices exceeding the closing price of $10.60 on March 6, 2025, meaning they will not yield cash from the merger.
• There will not be any public trading market for the newly acquired Topco Interests, limiting the liquidity for the SP Investors' reinvested capital.
• The value of the DAP Right (up to $3.00 per share) is contingent on the future monetization of VillageMD interests, introducing uncertainty regarding the total consideration received by shareholders.

Risks

• The merger may not be consummated if the Merger Agreement is terminated, which would impact the proposed transaction and the reinvestment.
• The value realized from the DAP Rights is uncertain and depends on the future monetization of VillageMD debt and equity interests, which may not reach the full $3.00 per share.
• There will be no public trading market for the Topco Interests acquired by the Investors, potentially limiting their ability to sell or dispose of their interests.
• The SP Investors' ability to dispose of Topco Interests will be subject to restrictions contained in the organizational documents of the applicable Topco and the Investors Agreement Documents.
• Transaction Litigation could arise, potentially involving Investor Related Parties, though indemnification provisions are in place.

Future Outlook

The document outlines the definitive steps towards the acquisition of Walgreens Boots Alliance by Sycamore Partners, including a corporate restructuring into 'Topcos' and the reinvestment by key existing shareholders. The parties anticipate the merger closing and the subsequent entry into definitive Investors Agreement Documents to govern their investments in the new entities. The future value of the DAP Rights, tied to VillageMD monetization, remains a forward-looking element.

Management Comments

• Pessina informed the Board that, should a transaction with Sycamore be in the best interests of all stockholders, he would consider taking any reasonable action necessary to facilitate it, including evaluating any request from Sycamore to roll over his shares.
• Pessina stated he would only engage with Sycamore about a potential rollover with the Board's full knowledge and approval, and would not condition his support of any transaction on his ability to participate.
• Pessina believed that reaching an agreement with Sycamore regarding the reinvestment terms remained possible, but no agreement had been reached as to the material terms until March 5, 2025.

Industry Context

This announcement signifies a major private equity acquisition in the retail pharmacy and healthcare sector, reflecting a trend of strategic divestitures and restructuring within large, diversified corporations. The carveout of businesses into 'Topcos' suggests a focus on optimizing specific segments, potentially to unlock value or streamline operations, a common strategy in private equity-led transformations.

Corporate Governance

Legal Proceedings

• The document mentions potential "Transaction Litigation" (stockholder litigation relating to the transactions) and includes provisions for indemnification and advancement of expenses for Investor Related Parties in such events.

Related Party Transactions

• The Reinvestment Agreement itself is a related party transaction, where existing major shareholders (SP Investors) are reinvesting into the acquiring entities.
• The Interim Investors Agreement details the termination of all other agreements, contracts, or understandings between any SP Related Party and the Company or its Subsidiaries, effective upon the Merger Closing, with exceptions for Transaction Agreements and the Voting Agreement.

Stakeholder Impact

• **Shareholders:** Will receive $11.45 cash per share and a DAP Right potentially worth up to $3.00 per share, representing the consideration for their shares.
• **SP Investors (Stefano Pessina & Alliance Sant Participations S.A.):** Will transition from direct shareholders of Walgreens Boots Alliance to equity holders in the new Topco entities, maintaining a significant stake and continued involvement in the restructured businesses.
• **Sycamore Partners (Sponsor Parties):** Will gain full control of Walgreens Boots Alliance through the merger and restructuring, with the benefit of a significant co-investment from the SP Investors.
• **Employees:** The restructuring into Topcos may imply changes to the corporate structure, which could have implications for employees, though not explicitly detailed in this filing.
• **Creditors:** The transaction involves debt financing (mentioned in the Interim Investors Agreement), which will impact the Company's capital structure and creditor relationships.

Next Steps

• Consummation of the Merger and the Restructuring (Carveout Transactions).
• The Reinvestment Closing, where SP Investors will pay the Aggregate Equity Investment Amount and receive Topco Interests.
• Entry into definitive Investors Agreement Documents by the relevant parties prior to or concurrently with the Merger Closing, or as soon as possible thereafter.
• The Company, applicable Parent Entities, Sale Committee, Shareholder Representative, and Rights Agent will enter into a Divested Asset Proceeds Rights Agreement prior to the Initial Closing.
• SP Investors will designate and appoint the Specified Holders Member to the Sale Committee prior to the Initial Closing.
• Organizational documents of Parent, Merger Sub, and the Topcos will be amended to reflect the agreements.

Key Dates

Keywords

Walgreens Boots Alliance, Sycamore Partners, Merger Agreement, Reinvestment Agreement, SEC Filing, Schedule 13D/A, Stefano Pessina, Private Equity Acquisition, Corporate Restructuring, DAP Rights, VillageMD, Beneficial Ownership